Cpf1 Nuclease Targeting for Low Off-Target Genome Editing

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current CRISPR-Cas9 systems suffer from imprecise specificity and off-target cleavage, posing significant challenges in clinical and other genome editing applications.

Innovation Solution

The use of Cpf1 nuclease, which has a single nuclease domain and a unique PAM motif, offers improved specificity and reliability for genome editing, allowing for precise targeting and reduced off-target activity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If CRISPR-Cas9 systems are used for genome editing, then genome editing capability is achieved, but off-target cleavage and imprecise specificity occur

Engineering Contradiction:

ImprovespecificityVSAvoidoff-target cleavage

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the nuclease parameter from Cas9 to Cpf1, which has fundamentally different molecular characteristics including a single nuclease domain instead of two, different PAM motif requirements (5'-TCrich-3' upstream vs. 5'-NGG-3' downstream), and different cleavage patterns. This parameter change resolves the contradiction by providing inherently higher specificity through the unique Cpf1 molecular mechanism while maintaining genome editing capability

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent segments the guide RNA into separate crRNA and tracrRNA components that must assemble and function together, adding an additional layer of specificity control. The separate crRNA contains the target-specific spacer sequence while tracrRNA provides structural framework and PAM interaction, creating a more refined targeting mechanism that reduces off-target effects compared to the single sgRNA approach

Inventive Principle:

Principle #1Segmentation

2Reliability

If Cpf1 nuclease with single nuclease domain is used, then specificity is improved, but device complexity changes

Engineering Contradiction:

ImprovespecificityVSAvoidnuclease domain structure

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent extracts and utilizes only the essential single RuvC nuclease domain of Cpf1, removing the need for the second HNH nuclease domain present in Cas9. This extraction simplifies the molecular architecture while maintaining cutting functionality, as the single RuvC domain is sufficient to create the necessary double-strand breaks when guided by the crRNA-tracrRNA complex

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent inverts the conventional CRISPR approach by using a single-nuclease-domain system (Cpf1) instead of the dual-nuclease-domain system (Cas9). This inversion leads to a different molecular mechanism where the single RuvC domain performs both strand cleavages through a unique mechanism, resulting in staggered cuts with 5' overhangs rather than blunt ends, thereby achieving higher specificity

Inventive Principle:

Principle #13The other way round (Inversion)

3Measurement precision

If unique PAM motif is used for targeting, then targeting precision is improved, but adaptability to different target sites decreases

Engineering Contradiction:

Improvetargeting precisionVSAvoidtarget site range

Core Design Contradiction:

Measurement precisionVSAdaptability or versatility

Solution Approach 1:

The patent applies local quality by requiring a specific 5'-TCrich-3' PAM motif immediately upstream of the target site for Cpf1 binding and cleavage initiation. This localized PAM requirement provides a precise molecular address system that enhances targeting precision, as the PAM sequence serves as a unique recognition element that distinguishes target sites from non-target sites with high specificity

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Cpf1 nuclease enables precise and reliable genome editing, minimizing off-target effects and enhancing the safety and efficacy of genetic modifications, particularly in human stem cells and microorganisms.

Implementation Method 1

The guide RNA: (i) comprises a sequence substantially complementary to a sequence comprised in a target nucleic acid strand

Methodology Applied

Scientific EffectComplementary base pairing:

Implementation Method 2

Cpf1 nuclease enables precise and reliable genome editing

Methodology Applied

Scientific EffectNuclease activity: Enzyme

Data Source

PatentUS12534715B2Nucleic acids for nuclease-mediated genome editing

Publication Date: 2026.01.27 WAGENINGEN UNIVERSITEIT

AI summary

The invention related to the field of genetic engineering tools, methods and techniques for gene or genome editing. Specifically, the invention concerns isolated polypeptides having nuclease activity, host cells and expression vectors comprising nucleic acids encoding said polypeptides as well as methods of cleaving and editing target nucleic acids in a sequence-specific matter. The poly peptides, nucleic acids, expression vectors, host cells and methods of the present invention have application in many fields of biotechnology, including, for example, synthetic biology and gene therapy.